Dear Sir

The risk of infection from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the outcomes of the COronaVIrus Disease 19 (COVID-19) in patients with immune mediated inflammatory diseases (IMIDs) remains challenging. Whether treatments with immunosuppressive and biologic therapies may increase the risk of infection, its severity and outcome is poorly investigated and, as a result, the discontinuation of these treatments has been suggested \[[@bib0005]\]. Earlier studies did not find a correlation between immunomodulating treatments and the prognosis of COVID-19 \[[@bib0010],[@bib0015]\], while drugs used in IMIDs are being tested to block the cytokine release syndrome associated with COVID-19 \[[@bib0020]\].

We report a prospective case series of 41 patients with IMIDs and concomitant COVID-19 infection. The diagnosis of COVID-19 infection was either confirmed with a positive PCR nasopharyngeal swab; or highly suspected in the presence of typical symptoms, including fever, dry cough, shortness of breath, or a lung computed tomography image consistent with COVID-19 pneumonia.

The clinical characteristics of the 41 IMID patients are summarized in [Table 1](#tbl0005){ref-type="table"} . Twelve patients had ulcerative colitis (UC), 9 Crohn's disease (CD), 8 psoriasis (Pso), 4 psoriatic arthritis (PsA), 5 rheumatoid arthritis (RA), and 3 had other related conditions. Twenty-four percent of patients were taking immunosuppressants, 17 % steroids, and 68 % a biologic. Thirteen patients (32 %) had relevant comorbidities, including hypertension, diabetes, obesity, chronic lung disease and malignancy. All patients developed COVID-19 symptoms, pneumonia was observed in 16 patients (40 %). Fourteen patients (34 %) were hospitalized with a median (IQ range) stay of 13 days (7--22). Ten patients (24 %) needed non-invasive ventilation while no patient was admitted to the intensive care unit but one died due to respiratory failure. This patient was a 79 year-old woman, with a diagnosis of RA since eight years, under concomitant prednisone 5 mg and methotrexate 12.5 mg daily. She had hypertension and chronic obstructive polmonary disease, and had a history of past tuberculosis. She was hospitalized for pneumonia and died two days after hospitalization.Table 1Characteristics of thePatients with IMID and concomitant COVID-19 (n = 41).Table 1Age at diagnosis of COVID-1948 (31.0−57.5)**Female**24 (59)**Region** Lombardy29 (71) Other12 (29)**IMID diagnosis** Ulcerative colitis12 (29) Crohn's disease9 (22) Psoriasis8 (20) Psoriatic arthritis4 (10) Rheumatoid arthritis5 (12) Ankylosing spondylitis1 (2.0) Systemic sclerosis1 (2.0) Systemic lupus erythematosus1 (2.0)**Long-term medications** Any immunosuppressants10 (24)Prednisone7 (17)Azathioprine1 (2.0)Methotrexate6 (15) Hydroxychloroquine3 (7.0) Any biologic therapy28 (68)Tumor necrosis factor inhibitors13 (32)Adalimumab10 (24)Infliximab2 (4)Etanercept1 (2)Interleukin-12/23 blocker (Ustekinumab)6 (15)Interleukin-23 blockers2 (5.0)Guselkumab1 (2)Risankizumab1 (2)Interleukin-17 blocker (Ixekizumab)2 (5.0)Rituximab1 (2.0)Belimumab1 (2.0)Vedolizumab1 (2.0) Baricitinib1 (2.0) Apremilast1 (2.0)**Clinical trial partecipants**2 (5.0)**Exposure risk** High risk work[\*](#tblfn0005){ref-type="table-fn"}9 (22) Contact with confirmed or suspected COVID patients23 (58) No strict adherence to oprevention measures23 (56) In- out-patient visits (within 14 days from COVID infection)9 (23)**Smoking** Past10 (24) Active3 (7.0)**Comorbidities**13 (32) Hypertension3 (7.0) Metabolic disorders [§](#tblfn0010){ref-type="table-fn"}6 (15) Chronic lung diseases2 (5.0) Malignancy [§§](#tblfn0015){ref-type="table-fn"}2 (5.0)**Positive rhinopharyngeal swabs**25 (61)**COVID-related symptoms**41 (100) Gastro-intestinal symptoms16 (39)**COVID-related pneumonia**16 (40)**Discontinuation of IMID therapy**24 (59)**Hospitalization**14 (34) Use of supplementary oxigen10 (24) Intensive Care Unit0 (0.0)**Death**1 (2.0)[^1][^2][^3][^4]

The patients that were hospitalized were older than the non-hospitalized patients \[median (IQ range) age was 55 (46--74) compared to 43 (30--53), p = 0.02\]. No differences in terms of IMID was found in the hospitalized population (p = 0.30). However, those subjects with rheumatological diseases needed more oxygen therapy compared to patients with a diagnosis of inflammatory bowel diseases (IBD) or psoriasis (p = 0.03). The subjects with comorbidities were more frequently hospitalized (p = 0.0003), and needed more oxygen supplementation (p = 0.0001). Finally, therapy with steroids increased the risk for the need of oxygen (p = 0.007). No association was found between the use of biologic therapy and the risk of hospitalization and need for oxygen therapy. A logistic regression analysis was performed. The presence of risk of hospitalization and risk of oxygen need were the outcome variables (or dependent variable) (i.e. binomial variables taking the value 1 if hospitalization and/or need of oxygen were occurred, and the value 0 if they don't). All the parameters described in [Table 2](#tbl0010){ref-type="table"} were employed as explanatory variables (or independent variables). Univariable analysis was used to identify candidate predictors. Then, a multivariable model was fitted using a \"backwards elimination procedure\". All variables with p \< 0.05 were retained in the model. Multivariable analysis revealed that only coexisting comorbidities were associated with increased risk of hospitalization and oxygen therapy **(** [Table 2](#tbl0010){ref-type="table"} **).** Table 2Influence of baseline parameters on the probability of hospitalization and need of supplementary oxygen.Table 2Risk of hospitalizationRisk of oxygen needUnivariate analysisMultivariate analysisUnivariate analysisMultivariate analysisParametersOR (95 % CI)*p*OR (95 % CI)*p*OR (95 % CI)*p*OR (95 % CI)*p***Age at diagnosis**1.06 (1.00−1.11)*0.01*1.12 (1.03−1.21)*0.003***Gender**4.27 (1.08−16.8)*0.03*1.58 (0.37−6.64)0.53**Use of steroids**6.94 (1.13−42.3)*0.03*14.5 (2.18−96.43)*0.005***Immunosuppressants**[\*](#tblfn0020){ref-type="table-fn"}3.2 (0.60−16.9)0.172.89 (0.52−16.0)0.22**Biologic therapy**0.63 (0.15−2.53)0.510.52 (0.11−2.33)0.39**Comorbidities**[§](#tblfn0030){ref-type="table-fn"}20.0 (3.76−106.1)*0.0004*13.8 (2.23−85.1)*0.004*60.7 (5.98−616.6)*0.0005*60.7 (5.98−616.6)*0.0005***IMID diagnosis IBD**[\*\*](#tblfn0025){ref-type="table-fn"}0.23 (0.05−0.95)*0.04*0.15 (0.02−0.87)*0.03***Psoriasis**2.3 (0.47−11.0)0.291.04 (0.17−6.22)0.96**Rheumatological diseases**[§§](#tblfn0035){ref-type="table-fn"}2.62 (0.65−10.58)0.176.25 (1.32−29.3)*0.02*[^5][^6][^7][^8]

Immunosuppression is expected to weaken the immune system response in patients with COVID-19 infection and concomitant IMID and possibly lead to worse outcomes. However, some studies suggest that active disease, older age and comorbidities may also be associated with COVID-19 negative outcomes, such as pneumonia, hospitalization and death \[[@bib0025]\]. Our data confirm that the presence of comorbidities, such as hypertension, diabetes, obesity and chronic lung disease, may increase the risk of hospitalization and the need of oxygen supplementation \[[@bib0030]\]. Despite limitations created by a small sample size, our study suggests using caution especially when administering steroid therapy, wheras biologic therapy seems safe since no association between the use of biologic therapy and a worse pattern of COVID-19 infection was observed.

In conclusion, patients with IMID and on a stable steroid-free remission under immunosuppression are not at increased risk of worse outcomes from COVID-19. Caution should be paid to older patients with comorbidities and concomitant chronic glucocorticoid intake.
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[^1]: IMID Immuno-Mediated Inflammatory Diseases; Data are presented as medians (interquartile range) or percentages when appropriate.

[^2]: 8 health workers, 1 police officer.

[^3]: Metabolic disorders include diabetes, obesity, metabolic syndrome.

[^4]: 1 renal carcinoma, 1 prostate cancer.

[^5]: Immunosuppressants: Azathioprine or Methotrexate.

[^6]: IBD, inflammatory bowel disease.

[^7]: comorbidities included arterial hypertension, diabetes, obesity, metabolic syndrome, chronic lung disease, renal cancer and prostate cancer.

[^8]: rheumatological diseases included psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic sclerosis and systemic lupus erythematosus.
